La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92130, USA.
Novo Nordisk Research Center Seattle, Inc., 530 Fairview Ave N, Seattle, WA, 98109, USA.
BMC Immunol. 2018 Mar 21;19(1):12. doi: 10.1186/s12865-018-0250-3.
Type 1 diabetes (T1D) is thought to be an autoimmune disease driven by anti-islet antigen responses and mediated by T-cells. Recent published data suggests that T-cell reactivity to modified peptides, effectively neoantigens, may promote T1D. These findings have given more credence to the concept that T1D may not be solely an error of immune recognition but may be propagated by errors in protein processing or in modifications to endogenous peptides occurring as result of hyperglycemia, endoplasmic reticulum (ER) stress, or general beta cell dysfunction. In the current study, we hypothesized that diabetes-associated epitopes bound human leukocyte antigen (HLA) class I poorly and that post-translational modifications (PTM) to key sequences within the insulin-B chain enhanced peptide binding to HLA class I, conferring the CD8+ T-cell reactivity associated with T1D.
We first identified, through the Immune Epitope Database (IEDB; www.iedb.org ), 138 published HLA class I-restricted diabetes-associated epitopes reported to elicit positive T-cell responses in humans. The peptide binding affinity for their respective restricting allele(s) was evaluated in vitro. Overall, 75% of the epitopes bound with a half maximal inhibitory concentration (IC50) of 8250 nM or better, establishing a reference affinity threshold for HLA class I-restricted diabetes epitopes. These studies demonstrated that epitopes from diabetes-associated antigens bound HLA with a lower affinity than those of microbial origin (binding threshold of 500 nM for 85% of the epitopes). Further predictions suggested that diabetes epitopes also bind HLA class I with lower affinity than epitopes associated with other autoimmune diseases. Therefore, we measured the effect of common PTM (citrullination, chlorination, deamidation, and oxidation) on HLA-A*02:01 binding of insulin-B-derived peptides, compared to native peptides. We found that these modifications increased binding for 44% of the insulin-B epitopes, but only 15% of the control peptides.
These results demonstrate that insulin-derived epitopes, commonly associated with T1D, generally bind HLA class I poorly, but can be subject to PTM that improve their binding capacity and may, in part, be responsible for T-cell activation in T1D and subsequent beta cell death.
1 型糖尿病(T1D)被认为是一种自身免疫性疾病,由抗胰岛抗原反应驱动,并由 T 细胞介导。最近发表的数据表明,T 细胞对修饰肽(有效是新抗原)的反应性可能促进 T1D。这些发现使人们更加相信 T1D 可能不仅仅是免疫识别的错误,而可能是由于蛋白质加工错误或内源性肽的修饰引起的,这些修饰是由于高血糖、内质网(ER)应激或一般β细胞功能障碍引起的。在本研究中,我们假设与糖尿病相关的表位与人类白细胞抗原(HLA)I 类结合不良,并且胰岛素 B 链内的关键序列的翻译后修饰(PTM)增强了肽与 HLA I 类的结合,赋予与 T1D 相关的 CD8+T 细胞反应性。
我们首先通过免疫表位数据库(IEDB;www.iedb.org)确定了 138 个已发表的与人类 T 细胞阳性反应相关的 HLA I 类限制的糖尿病相关表位。通过体外评估它们各自限制等位基因的肽结合亲和力。总体而言,75%的表位以半最大抑制浓度(IC50)为 8250 nM 或更好的方式结合,为 HLA I 类限制的糖尿病表位建立了参考亲和力阈值。这些研究表明,来自糖尿病相关抗原的表位与 HLA 的结合亲和力低于微生物来源的表位(85%的表位的结合阈值为 500 nM)。进一步的预测表明,糖尿病表位与其他自身免疫性疾病相关的表位相比,与 HLA I 类的结合亲和力也较低。因此,我们测量了常见翻译后修饰(瓜氨酸化、氯化、脱酰胺和氧化)对与胰岛素 B 衍生肽相比,与 HLA-A*02:01 结合的影响。我们发现这些修饰增加了 44%的胰岛素 B 表位的结合,但只有 15%的对照肽结合。
这些结果表明,通常与 T1D 相关的胰岛素衍生表位与 HLA I 类的结合亲和力较差,但可以发生翻译后修饰,从而提高其结合能力,这可能部分导致 T1D 中的 T 细胞激活和随后的β细胞死亡。